P21 for Health & Longevity

Created on 10/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

P21 is a short laboratory-made peptide, copied from part of a natural nerve-cell growth signal, taken to support memory and the aging brain. No published study has given it to a person. Almost every positive animal finding comes from the laboratory that invented and patents it, and an outside test of its core mechanism did not succeed. The only supply is research-grade material of unverified identity and sterility. (Full Review)

Protocol

Standard human protocol
None exists
No dose, interval, duration or route for human use established in any published study
Competing approach — injection and intranasal
100–500 µg daily, subcutaneous
Or 500 µg–1 mg intranasally; grey-market extrapolations with no approved clinical dose
Published oral dose (rodent)
60 nmol per gram of feed
Roughly 162 nmol per mouse per day over 18 months; the regimen behind most efficacy claims
Time to effect
Alzheimer-model mice
9 to 18 months
Continuous dosing before benefits were read out
Aged rats
3 months
Continuous dosing before retinal benefits were read out
Humans
Unknown
No short-term readout has been validated

Benefits

Contraindications
  • Pregnant and breastfeeding women
  • People with active or recent cancer
  • Children and adolescents
  • Anyone without an identity-verified, sterility-tested product
Key Interactions
Theoretical (inferred from mechanism)
  • Lithium and other GSK-3β inhibitors (tideglusib)
  • Other BDNF-raising compounds (7,8-dihydroxyflavone, 7,8-DHF prodrugs)
  • Supplements that raise BDNF (curcumin, omega-3 fatty acids)
  • Immunosuppressants and biologic agents (tocilizumab, sarilumab)

Risk & Side Effects

  • High:
  • Medium:
  • Low: CNTF-class systemic adverse effects; injection-site reactions; immune response to the peptide
  • Speculative: Substandard or contaminated grey-market product; unintended cell proliferation from GSK-3β inhibition

Monitoring

Marker Target Why
Body weight No established target; track percentage change from own baseline Safety check; a sustained fall stops use
hs-CRP Below 1.0 mg/L Safety check; a rise changes use
Serum BDNF No established target; track change from own baseline Proposed mechanism; not a validated surrogate

Cadence: Baseline before any use; no validated cadence. Comparable practice repeats the safety set at 4 weeks, at 12 weeks and every 6 months thereafter, with body weight checked weekly throughout.

Qualitative Assessment

  • Appetite
  • Body composition and strength
  • Memory and word-finding
  • Sleep quality and duration
  • Injection-site condition